Technical Data
P4444-27E
Polyethylene Glycol (PEG)
Description:
Polyethylene glycol (PEG) is a family of long chain polymers attached to a glycerine backbone. It is a nonionic, nontoxic, biocompatible, strongly hydrophilic polymer, which has a large exclusion volume in aqueous solution (1). The covalent attachment of PEG is now commonly used to modify a variety of proteins and drugs (2,3). The modification of a biopharmaceutical with polyethylene glycol (PEG) increases its hydrodynamic radius, reduces immunogenicity and proteolytic cleavage. Other benefits include decelerated renal excretion, improved stability towards proteolysis and increased solubility of the biopharmaceutical in aqueous solutions (4). As examples, PEG-adenosine deaminase (Adagen®) is used for the treatment of severe combined immunodeficiency syndrome, PEG–asparaginase (Oncaspar®) is used for the treatment acute lymphoblastic leukemia, PEG–interferon alpha-2a (Pegasys®) is used for the treatment Hepatitis C, Branched PEG–anti-VEGF aptamer (Pegaptanib, Macugen™) is used for the treatment Macular degeneration(age-related) (5). An anti-PEG antibody can be used to monitor a drug’s pharmacokinetics, including distribution, metabolism and excretion.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilutions:
ELISA (Indirect): 1:500-1:2000
ELISA (Blood): 1:100
ELISA (Plasma): 1:10
Western Blot: 200-250ng
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG12J1Affinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceMouse
Concentration:
~0.5mg/ml
Immunogen:
PEG-conjugated protein
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 50% glycerol.
Specificity:
Reacts with PEGylated proteins such as PEG-GCSF, PEG-Erythropoietin and PEG-Interferon, but does not react to unmodified form of the same proteins.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
General References:
1. Guiotto, A. et al. (2004) Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation. Bioorg. Med.Chem. 12, 5031. 2. Wong, S.S. (1991) Reactive groups of proteins and their modifying agents. In Chemistry of protein conjugation and cross-linking, p. 13, CRC Press. 3. Caliceti, P. et al.(1993) Active site protection of proteolytic enzymes by poly(ethylene glycol) surface modification. J. Bioact. Comp. Polym. 8, 41. 4. Frank Leenders, celares GmbH, Berlin, Germany.(2006) PEGylation technology and biopharmaceuticals. Biopharmaceuticals. 6, 39-40. 5. Francesco M.Veronese, Gianfranco Pasut. (2005) PEGylation, successful approach.